Do You Need a Prescription for REVIVE Blend? Is It Legal to Buy Online?

Section 503(b) of the Federal Food, Drug, and Cosmetic Act makes a drug prescription-only when it is not safe for use except under the supervision of a licensed practitioner, and dispensing it without a prescription is treated as misbranding. A sterile four-peptide injectable that includes two growth hormone secretagogues fits that description. The rule binds the dispenser, which is why sellers who skip it label their vials as something other than medicine.

Section 503A of the same Act exempts a drug compounded by a licensed pharmacist "for an identified individual patient based on the receipt of a valid prescription order" from the new-drug approval requirement and several labeling and manufacturing rules. Without the prescription the exemption does not apply. That is why a lawful REVIVE vial has your name on it. The broader background is in are peptides legal in the US.

REVIVE is a brand name for a combination and has no FDA file. The FDA reviews the bulk substances a 503A pharmacy compounds from: here GHK-Cu, CJC-1295, ipamorelin and TB-500. So "is REVIVE legal" is four questions, and the blend's answer is only as settled as its least settled component. The blend itself is explained in what is REVIVE Blend.

Both secretagogues went through the FDA's Pharmacy Compounding Advisory Committee in full. On 29 October 2024 the committee considered ipamorelin and ipamorelin acetate, evaluated for growth hormone deficiency and postoperative ileus, and voted 0 in favour, 12 against, with 1 abstention, on adding them to the 503A Bulks List, citing a lack of safety and efficacy data for those uses. On 4 December 2024 it considered the CJC-1295 family, evaluated for growth hormone deficiency, and voted 0 to 13 against the free base, 1 to 12 against the acetate, and 0 to 13 against each of the three DAC forms.

Two things about those votes matter. The committee evaluates a substance for the uses in its nomination, here conditions for which FDA-approved drugs already exist, not for every use a physician might prescribe it for. And a committee vote is a recommendation, not a rule. As of September 2026 the FDA has issued no final determination for either. On the FDA's safety-risks page, current as of 22 April 2026, both appear among substances "nominated but withdrawn" rather than in 503A Category 2. Ipamorelin acetate keeps a Category 2 entry only on the separate 503B list for outsourcing facilities, which is not the pathway a patient-specific 503A prescription uses.

On 15 April 2026 the FDA announced the removal of twelve peptides from Category 2, effective about a week later, and TB-500 was one of them. On 23 July 2026 the committee reviewed TB-500 for wound healing and voted 8 to 6, with one abstention, to recommend adding it, as the free base and the acetate, to the 503A Bulks List. FDA's own scientists had recommended against inclusion, citing insufficient safety, efficacy and characterisation data. The FDA's final determination is pending. More is in is TB-500 safe.

Injectable GHK-Cu was among the same twelve April removals. It was not on the July agenda; the FDA has said the committee will consider it at a meeting before the end of February 2027. Until then it is no longer flagged and not yet reviewed for the positive list.

None of the four is in 503A Category 2 today. One has a positive recommendation awaiting FDA action, one is scheduled for review, and two have negative recommendations with no final rule. A "no" vote is not a ban. All four remain legal for a physician to prescribe and a state-licensed pharmacy to compound, and none is an FDA-approved drug. See are peptides FDA approved.